Rocket Companies reported a $68 million GAAP loss for fiscal 2025 — on $6.7 billion in revenue. But the 10-K reveals two fundamentally different companies hiding in one set of financials: a pre-acquisition originator that burned $359M in EBITDA over nine months, and a post-acquisition servicing platform that generated $592M in Q4 EBITDA alone. At $76.1 billion maximum dilution, the stock prices in a company that doesn't yet fully exist in GAAP.
International Flavors & Fragrances reported an operating loss of $382 million in FY 2025 — yet management called it 'solid performance.' The disconnect: 72% of IFF's $2.1 billion Credit Adjusted EBITDA comes from add-backs. At GAAP EBITDA of $580 million, leverage isn't 2.6x — it's 9.3x. With $3.84 billion in cumulative goodwill impairments across three reporting units, six divestitures in 18 months, and a dividend payout ratio of 161% at the already-cut level, IFF's 10-K documents a $26 billion acquisition being systematically dismantled to save the company it was supposed to transform.
International Paper spent $7.2 billion to acquire DS Smith, took a $2.47 billion goodwill impairment within eleven months, then announced it would spin off the acquired business. But the impairment is only the first layer. Our 10-K analysis reveals $3.85 billion in total first-year value destruction — including a $518 million foregone tax shield and $867 million in integration cash drain — plus $1.23 billion in annual recurring charges that will weigh on earnings for 14+ years.
Bank of New York Mellon reported record revenue of $20.1 billion and 28.4% ROTCE in FY 2025 — numbers that suggest an efficiently run financial institution earning outsized returns. But the 10-K reveals a paradox: one segment generates 49% operating margins on infrastructure that moves $614 billion in securities, while another runs at 17% margins with declining revenue and $16.8 billion in goodwill from an 18-year-old acquisition. At 15.5x earnings, the market prices one company. The filing shows it's two.
Boston Scientific has written off $9.9 billion in cumulative goodwill impairments — 35% of every dollar ever booked. Yet in FY2025, the serial acquirer's ROIC crossed 9.1% for the first time in 20 quarters. Then BSX announced $14.5 billion for Penumbra, which will spike leverage from 1.95× to ~4.1× net debt/EBITDA — landing 0.65× below the covenant ceiling. The 10-K reveals a company at a binary inflection: the acquisition lifecycle model either compounds from here, or a history of goodwill destruction repeats at unprecedented scale.
Medtronic delivered Q3 FY2026 revenue of $9.02 billion — its highest growth rate in 10 quarters at 8.7% year-over-year — with non-GAAP EPS of $1.36 beating consensus by $0.02. The stock fell 3.2% anyway. The 10-Q filing reveals why: $306-356M in MiniMed separation costs are front-loaded into the income statement, a $1.146B antitrust verdict went unmentioned in the press release, and Medical Surgical's $19.8B goodwill sits on a cushion of just 12%. Cardiovascular acceleration — up 13.8% with PFA capturing 80% of the EP market — is the real story, but the separation repricing makes it harder to see.